Mediastinal neoplasms in patients with Graves disease: a possible link between sustained hyperthyroidism and thymic neoplasia?
© Boyd and Juskevicius; licensee BioMed Central Ltd. 2012
Received: 10 April 2012
Accepted: 23 July 2012
Published: 23 July 2012
Anterior mediastinal masses are a rare but well documented finding in Graves disease. The vast majority of these lesions represents benign thymic hypertrophy and regress after treatment of the hyperthyroidism. A small percentage of these cases however represent neoplastic/malignant diseases which require further treatment.
12 year old boy with one year history of refractory Graves disease was found to have an anterior mediastinal mass and underwent curative thyroidectomy for sustained hyperthyroidism. Cervical lymphadenopathy was detected during the procedure and biopsy was obtained. A 23 year old woman who presented with a one month history of hyperthyroid symptoms, was diagnosed with Graves disease and also was found to have an anterior mediastinal mass on imaging. Biopsy of the anterior mediastinal mass was obtained and subsequently the patient underwent robotic thymectomy. Histologic examination and immunophenotyping of the cervical lymph node in a 12 year old boy revealed neoplastic proliferation of T lymphoblasts diagnostic of T lymphoblastic leukemia/lymphoma. Examination of the anterior mediastinal mass biopsy in the 23 year old woman revealed type B1 thymoma which was confirmed after examination of the subsequent robotic thymectomy specimen.
This is the first reported case of T cell lymphoblastic lymphoma and the third reported case of thymoma associated with sustained hyperthyroidism due to Graves disease. These cases indicate that an anterior mediastinal mass in a patient with active Graves disease may be due to a neoplastic cause, which may require definitive treatment. Caution should be exercised when dismissing a mediastinal mass as benign thymic hyperplasia in patients with active Graves disease.
KeywordsGraves disease Hyperthyroidism Thymoma T Lymphoblastic leukemia/lymphoma Thymic hyperplasia
Graves disease (GD) is an autoimmune disease caused by self-reactive plasma cells which produce antibodies to the thyrotropin receptor that stimulate thyroid-stimulating hormone receptors and increase the production of thyroid hormone . The relationship between Graves disease (GD) and mediastinal masses is nearly a century old having been first identified in a patient with thymic hyperplasia secondary to GD described by Halsted in 1914 . With a well known benign cause of anterior mediastinal masses (AMM) in Graves disease, there is a tendency to forego tissue biopsy and re-evaluate at an unspecified time after thyroid ablation/thyroidectomy [2–5]. Here we describe two patients with neoplastic anterior mediastinal masses associated with GD, illustrating that this may not be safe approach to all patients with anterior mediastinal masses and GD.
The second patient is a 23-year old female without significant medical history who was transferred to our institution with increasing shortness of breath, dysphagia, cervical lymphadenopathy and a mediastinal mass identified on chest CT (Figure 1C). A TSH level was below the minimum detection limit of 0.02 uIU/m as well as a free T3 of 12.2 pg/mL (reference range: 3.4-4.8). Biopsies of the anterior mediastinal mass were obtained and showed a type B1 thymoma. Cervical lymph node biopsy revealed dermatopathic lymphadenitis. The patient underwent a robotic thymectomy and a diagnosis of type B1 thymoma was confirmed (Figure 1D). Patient had an uneventful post operative course and was discharged on post operative day 3.
Evaluating an AMM in the setting of GD can be challenging for the clinician. There is no systematic, formal evaluation of how best to manage AMM in the setting of GD . There is substantial variability in the rate of thymic involution as well as thymic size, shape and density even between individuals of the same age . A retrospective study of 109 patients with AMM treated with thymectomy found that all cases with malignancy had either symptoms referable to the thymus or a discrete mass rather than a diffusely enlarged thymus gland . The utility of this information is partially limited by the finding that a “discrete mass” was seen in 32% of thymic hyperplasias and 66% of histologically normal thymus glands . Also, symptoms anatomically referable to enlargement of the thymus (chest discomfort, chest pain and shortness of breath)  can frequently also be seen in GD . Prevailing wisdom from several recent case reports of thymic hyperplasia in GD is that caution should be used in evaluating AMM in the setting of GD given the known association with thymic hyperplasia [2–5]. Clinicians are urged to wait until after resolution of hyperthyroidism to follow up AMM in the absence of features concerning for malignancy (invasion, calcifications, cysts or septations) on imaging [2–5]. Reduction of thymic enlargement after achieving a euthryoid state can vary from 2 months up to 2 years  which could complicate following up a possibly neoplastic mediastinal mass.
These cases represent two examples of mediastinal neoplasms seen in association with GD. While the first patient represents the first documented case of T-LBL/L seen in association with GD, there are two prior case reports of thymoma occuring with GD [8, 9]. On the other hand, occurance of T-LBL/L with other autoimmune diseases is well documented [10–17].
Autoimmunity alters the environment of the immune system with positive selection/expansion of autoreactive T-cells in the thymus. Thymic hyperplasia is a representation of how GD, in particular, alters the microenvironment of the thymus. This is thought to be due to the hyperthyroidism associated with active GD. It is known that thyroid hormones (TH) are able to induce thymic epithelial cell (TEC) proliferation which produces cytokines (including IL-1) . T3 also enhances thymic hormone thymulin secretion by TECs . In turn, cytokines (e.g. IL-1) and thymulin stimulate and enhance thymocyte (immature T-cell precursor) proliferation. Thymocyte differentiation occurs as the cells migrate within thymic lobules interacting with microenvironment . In active GD, thymic microenvironment may be altered due to increased proliferation of TECs driven by TH. It is unclear if thymic environment altered by the state of sustained hyperthyroidism, including increased proliferative drive on maturing thymocytes and, possibly, abnormal differentiation, may contribute to the development of genetic lesions resulting in T LBL/L in susceptible individuals. Likewise it is not unreasonable to postulate that TH driven TEC proliferation may contribute to the pathogenesis of thymoma, which is a neoplasm of thymic epithelial cells. The two patients illustrated not only raise the possibility of association between GD and mediastinal neoplasms but represent a possible reason for caution in using a watch-and-wait approach to anterior mediastinal masses in patients with GD.
This is the first reported case of T lymphoblastic lymphoma/leukemia and the third reported case of thymoma developing in patients with sustained poorly controlled hyperthyroidism due to Graves disease. Given the known physiologic interactions between thyroid hormones and thymic microenvironment, these cases may indicate a possible link between a sustained hyperthyroidism and the development of thymic neoplasia. In addition, our cases indicate that an anterior mediastinal mass in a patient with active Graves disease may be due to a neoplastic cause, which may require definitive treatment. Caution should be exercised when dismissing a mediastinal mass as benign thymic hyperplasia in patients with active Graves disease.
This case report was based on the existing data, and the patients’ identification was kept confidential in this study. This case report does not meet definition of human or animal subject research by University and Medical Center Institutional Review Board of East Carolina University, and no ethical approval was necessary for this study.
Anterior mediastinal masses
- Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN: American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011, 21: 593–646. 10.1089/thy.2010.0417PubMedView ArticleGoogle Scholar
- Popoveniuc G, Sharma M, Devdhar M, Wexler JA, Carroll NM, Wartofsky L, Burman KD: Graves’ disease and thymic hyperplasia: the relationship of thymic volume to thyroid function. Thyroid 2010, 20: 1015–8. 10.1089/thy.2009.0383PubMedView ArticleGoogle Scholar
- Yacoub A, Gaitonde DY, Wood JC: Thymic hyperplasia and Graves disease: management of anterior mediastinal masses in patients with Graves disease. Endocr Pract 2009, 15: 534–9. 10.4158/EP09025.ORRPubMedView ArticleGoogle Scholar
- Budavari AI, Whitaker MD, Helmers RA: Thymic hyperplasia presenting as anterior mediastinal mass in 2 patients with Graves disease. Mayo Clin Proc 2002, 77: 495–9.PubMedView ArticleGoogle Scholar
- Yamanaka K, Nakayama H, Watanabe K, Kameda Y: Anterior mediastinal mass in a patient with Graves’ disease. Ann Thorac Surg 2006, 81: 1904–6. 10.1016/j.athoracsur.2005.07.081PubMedView ArticleGoogle Scholar
- Singla S, Litzky LA, Kaiser LR, Shrager JB: Should asymptomatic enlarged thymus glands be resected? J Thorac Cardiovasc Surg 2010, 1405: 977–83.View ArticleGoogle Scholar
- Chan WB, Yeung VT, Chow CC, So WY, Cockram CS: Gynaecomastia as a presenting feature of thyrotoxicosis. Postgrad Med J 1999, 75: 229–31.PubMed CentralPubMedView ArticleGoogle Scholar
- Levy Y, Afek A, Sherer Y, Bar-Dayan Y, Shibi R, Kopolovic J, Shoenfeld Y: Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Semin Arthritis Rheum 1998, 28: 73–9. 10.1016/S0049-0172(98)80039-5PubMedView ArticleGoogle Scholar
- Lee BW, Ihm SH, Shin HS, Yoo HJ: Malignant thymoma associated with myasthenia gravis, Graves’ disease, and SIADH. Intern Med 2008, 47: 1009–12. 10.2169/internalmedicine.47.0838PubMedView ArticleGoogle Scholar
- Olcay L, Koç A: Autoimmune hemolytic anemia preceding T-ALL in a five-year-old girl. Pediatr Hematol Oncol 2005, 22: 207–13. 10.1080/08880010590921478PubMedView ArticleGoogle Scholar
- Piernas S, Xicoy B, Grifols JR, Ribera JM: Autoimmune hemolytic anemia with positive direct antiglobulin test associated with T cell acute lymphoblastic leukemia. Med Clin (Barc) 2006, 126: 678–9. 10.1157/13087849View ArticleGoogle Scholar
- Tsuchihashi T, Kimura N, Niho Y, Oka Y, Ikuta T, Sumita I, Otsuka M, Mitsui T, Ohara Y: A case of cold agglutinin disease with T cell lymphoblastic lymphoma. Rinsho Ketsueki 1982, 23: 743–8.PubMedGoogle Scholar
- Uner AH, Abali H, Engin H, Akyol A, Ruacan S, Tan E, Güllü I, Altundağ K, Güler N: Myasthenia gravis and lymphoblastic lymphoma involving the thymus: a rare association. Leuk Lymphoma 2001, 42: 527–31. 10.3109/10428190109064612PubMedView ArticleGoogle Scholar
- Liu KL, Herbrecht R, Tranchant C, Gasser B, Warter JM, Wihlm JM, Oberling F: Malignant thymic lymphoblastic lymphoma and myasthenia gravis: an exceptional association. Nouv Rev Fr Hematol 1992, 34: 221–3.PubMedGoogle Scholar
- Hansen BA, Sørensen PS, Lauritzen MJ, Iversen J, Laulund S, Petrera JE, Nielsen JB, Paulson OB: A case of malignant lymphoma and myasthenia gravis. Scand J Haematol 1983, 31: 155–60.PubMedView ArticleGoogle Scholar
- Mortimer JE, Kidd P: Myasthenia gravis and lymphoblastic lymphoma antiacetylcholine receptor antibody as a tumor marker–a case report. Cancer Invest 1989, 7: 327–31. 10.3109/07357908909039858PubMedView ArticleGoogle Scholar
- Hirose Y, Masaki Y, Ebata K, Okada J, Kim CG, Ogawa N, Wano Y, Sugai S: T-Cell type acute lymphoblastic leukemia following cyclosporin A therapy for aplastic anemia. Int J Hematol 2001, 73: 226–9. 10.1007/BF02981942PubMedView ArticleGoogle Scholar
- Savino W, Dardenne M: Neuroendocrine control of thymus physiology. Endocr Rev 2000, 21: 412–43. 10.1210/er.21.4.412PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.